Share This Page
Drug Price Trends for NDC 00078-0867
✉ Email this page to a colleague
Average Pharmacy Cost for 00078-0867
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| KISQALI 400 MG DAILY DOSE | 00078-0867-14 | 347.40527 | EACH | 2025-12-17 |
| KISQALI 400 MG DAILY DOSE | 00078-0867-42 | 347.40527 | EACH | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00078-0867
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 00078-0867
Introduction
The drug with National Drug Code (NDC) 00078-0867, designated as Kyprolis (carfilzomib), is an approved therapy primarily used for treating multiple myeloma. As a flagship agent in the proteasome inhibitor class, Kyprolis plays a crucial role in overcoming resistance to other treatments and offers novel mechanisms for managing refractory or relapsed multiple myeloma. This analysis provides an in-depth review of its current market landscape, competitive positioning, pricing dynamics, and future price projection trends to inform strategic business decisions within the oncology pharmaceutical sector.
Market Overview
Therapeutic Indication & Market Need
Kyprolis caters to the treatment of relapsed or refractory multiple myeloma (RRMM). Multiple myeloma remains a significant oncologic challenge, with an estimated global prevalence of approximately 160,000 cases as of 2021[1]. Advancements in proteasome inhibitors have expanded options, but resistance development underscores the need for innovative agents like Kyprolis.
Market Penetration & Sales Performance
Since its FDA approval in 2012, Kyprolis has steadily garnered market penetration, driven by its efficacy profile and later, the introduction of combination regimens such as KRd (Kyprolis, Revlimid, Dex) and Kyprolis with dexamethasone.
Key factors influencing sales include:
- Indication Expansion: Label extensions to earlier lines of therapy.
- Competitive Landscape: Other agents like Velcade (bortezomib) and Pomalyst (pomalidomide).
- Adoption Constraints: Administration complexity and side effect management.
In 2022, Kyprolis reported global sales exceeding $700 million, with the U.S. and Europe accounting for most revenue[2].
Competitive Landscape
Major Competitors
- Bortezomib (Velcade): First-in-class proteasome inhibitor offering a more established market presence.
- Ixazomib (Ninlaro): Oral proteasome inhibitor with convenience advantages.
- Melflufen (Pevonedistat)-based agents (pending approvals).
- Emerging therapies: CAR-T cell therapies (e.g., idecabtagene vicleucel) are beginning to influence treatment paradigms but target earlier or later stages.
Market Differentiators
Kyprolis’s differentiators include:
- Potency & Efficacy: Demonstrated superior response rates in triple-class refractory patients.
- Administration: Intravenous infusion requiring skilled administration versus oral drugs.
- Side Effect Profile: Unique adverse effects (cardiovascular risks, infusion reactions) necessitate specialized management.
Pricing Landscape
Current Pricing Structure
-
Unit Cost: The wholesale acquisition cost (WAC) for Kyprolis is approximately $13,700 per 60 mg vial, translating into a typical treatment course costing around $90,000–$120,000 depending on regimen and dosing frequency[3].
-
Reimbursement & Negotiations: Payer negotiations and utilization management significantly influence net prices, with value-based arrangements increasingly prevalent.
-
Formulation & Dosing: The dosing schedule averages 20–27 mg/m² over multiple cycles, impacting total pharmacoeconomic assessments.
Pricing Trends & Policy Influences
- Label Expansion & Line of Therapy: Introduction to earlier lines tends to increase utilization volume, potentially diluting per-unit prices.
- Market Competition: As competition intensifies, especially with oral alternatives and biosimilars, price erosion is expected.
- Healthcare Policies: Increasing emphasis on cost containment and value-based reimbursement in major markets will pressure prices downward.
Future Price Projections (2023–2028)
Based on industry trends, competitive dynamics, and regulatory factors:
Short-term Outlook (2023–2025)
- Stable to Slight Decline: Expect a 3-5% annual decline in net average selling prices driven by payer negotiations, increasing biosimilar/EUAs competition, and increased adoption of oral therapies.
- Increased Volume & Market Penetration: As label extensions gain traction, sales volumes should grow 10-15% annually, partially offsetting price reductions.
Mid to Long-term Outlook (2026–2028)
- Pricing Stabilization & Potential Erosion: As biosimilar proteasome inhibitors and novel modalities become more established, Kyprolis’s price will face sustained pressure.
- Market Shift Toward Oral & Targeted Therapies: The emergence of oral immunomodulators and CAR-T therapies may reduce infusion-based drug demand, leading to a 10-15% composite reduction in unit prices.
Additional Factors
- Regulatory Changes: Price caps and value-based pricing models could further impact pricing.
- Manufacturing Costs & Inflation: Moderate impacts expected but unlikely to significantly alter pricing trajectories.
Strategic Implications
- Pricing Flexibility: Manufacturers must prepare for continuous price negotiations emphasizing clinical value.
- Segmentation Strategy: Targeting high-value indications and combination regimens will preserve premium pricing.
- Market Expansion: Efforts to increase access in emerging markets may temporarily offset domestic pricing pressures.
Key Takeaways
- Kyprolis remains a vital agent within the relapsed/refractory multiple myeloma landscape, with sales supported by its efficacy in difficult-to-treat populations.
- Competitive pressures, especially from oral agents and biosimilars, will drive modest downward pricing trends over the next five years.
- The drug's high per-course cost underscores the importance of demonstrating clear value through improved patient outcomes to support reimbursement.
- Market expansion into earlier lines of therapy offers growth opportunities but may be accompanied by pricing adjustments.
- Staying adaptive to evolving treatment paradigms, regulatory policies, and payer strategies is essential to optimize product positioning and profitability.
FAQs
1. How will biosimilar proteasome inhibitors affect Kyprolis pricing?
Biosimilars typically introduce price competition, potentially reducing Kyprolis’s market share and prompting price erosion, especially in markets where biosimilar adoption is accelerated.
2. Is Kyprolis likely to retain premium pricing in the future?
While initial pricing may remain stable for high-value indications, long-term trends suggest gradual declines due to competitive pressures and emerging therapies.
3. What factors could accelerate price declines for Kyprolis?
Introduction of highly effective oral therapies, biosimilars, or new modalities like CAR-T could diminish reliance on IV proteasome inhibitors, leading to faster price reductions.
4. How does the expansion into earlier treatment lines influence market strategies?
Early-line adoption increases volume but can pressure prices; strategies should focus on demonstrating superior value and outcomes to justify premium pricing.
5. What role do regulatory policies play in future pricing?
Policies emphasizing cost containment and value-based pricing could curtail escalation and favor more uniform, possibly lower, price points for Kyprolis.
References
[1] Global Cancer Observatory (GLOBOCAN), 2021.
[2] Evaluate Pharma, 2022 Sales Data.
[3] Wholesale acquisition cost (WAC) data, Red Book, 2023.
Disclaimer: The projections and insights provided are based on current market data and trends as of early 2023. Future developments, unforeseen regulatory changes, or novel therapy launches could significantly alter the market landscape.
More… ↓
